No updates for settling balance for differences on targeted therapy for cancer ‘Tarceva’

The pharmaceutical distribution industry raised complaints since they have not been able to settle balance for differences generated by the drug price cut of ‘Tarceva,’ a Roche Korea’s targeted therapy for cancer.

The Tarceva Tab’s drug price dropped from KRW 49,697 to KRW 34,788 for 100mg and from KRW 55,727 to KRW 39,009 for 150mg due to its patent expiration on the 31^st of October last year...